PMID- 27397060
OWN - NLM
STAT- MEDLINE
DCOM- 20170614
LR  - 20181202
IS  - 1880-3873 (Electronic)
IS  - 1340-3478 (Print)
IS  - 1340-3478 (Linking)
VI  - 24
IP  - 2
DP  - 2017 Feb 1
TI  - Effect of Glycemic Control on Chylomicron Metabolism and Correlation between 
      Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 
      Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
PG  - 157-168
LID - 10.5551/jat.32409 [doi]
AB  - AIM: Glucagon-like peptide-1 can reduce both postprandial plasma glucose (PG) and 
      chylomicron (CM) levels in patients with type 2 diabetes. However, there have 
      been no reports regarding the relationship between the postprandial metabolism of 
      PG and CM. METHODS: Patients with type 2 diabetes who were admitted for glycemic 
      control were randomized to insulin alone (Ins; n=16) or insulin plus vildagliptin 
      100 mg (InsV; n=16) groups. The insulin dose was adjusted to maintain normal 
      blood glucose levels. The daily profiles of serum TG, remnant lipoprotein 
      cholesterol (RemL-C), and apolipoprotein B48 (ApoB48) were estimated by frequent 
      blood collection on admission and before discharge, and the daily glucose 
      fluctuation profile was also estimated using continuous glucose monitoring (CGM) 
      before discharge. RESULTS: The daily profiles of serum TG and RemL-C indicated a 
      significant decrease before discharge compared with on admission; however, no 
      significant changes in serum ApoB48 levels were observed in either group. At 
      discharge, daily glucose fluctuation profile and the change in the serum ApoB48 
      level from fasting to the peak of the daily profile was significantly smaller in 
      the InsV group than in the Ins group. The increment of serum ApoB48 level was 
      significantly correlated with the mean amplitude of glycemic excursions 
      calculated using CGM data only in the Ins group (R(2)= 0.5242,P＜0.001). 
      CONCLUSIONS: Short-term glycemic control decreased serum TG and RemL-C levels, 
      but not ApoB48 levels, and the postprandial metabolism of PG and CM might be 
      regulated by the same mechanism except GLP-1 effect.
FAU - Okajima, Fumitaka
AU  - Okajima F
AD  - Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon 
      Medical School.
FAU - Emoto, Naoya
AU  - Emoto N
FAU - Kato, Katsuhito
AU  - Kato K
FAU - Sugihara, Hitoshi
AU  - Sugihara H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160708
PL  - Japan
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
RN  - 0 (Apolipoprotein B-48)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Chylomicrons)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Lipoproteins)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 0 (Triglycerides)
RN  - 0 (lipoprotein cholesterol)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/*analogs & derivatives/pharmacology
MH  - Adult
MH  - Aged
MH  - Apolipoprotein B-48/metabolism
MH  - Biomarkers/*blood
MH  - Blood Glucose/*metabolism
MH  - Cholesterol/metabolism
MH  - Chylomicrons/*metabolism
MH  - Diabetes Mellitus, Type 2/drug therapy/*metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/pharmacology
MH  - Drug Therapy, Combination
MH  - Fasting
MH  - Female
MH  - Follow-Up Studies
MH  - Glycemic Index
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology
MH  - Insulin/*pharmacology
MH  - Lipoproteins/metabolism
MH  - Male
MH  - Middle Aged
MH  - Nitriles/*pharmacology
MH  - *Postprandial Period
MH  - Prognosis
MH  - Pyrrolidines/*pharmacology
MH  - Triglycerides/metabolism
MH  - Vildagliptin
MH  - Young Adult
PMC - PMC5305676
COIS- All authors declare no conflict of interest.
EDAT- 2016/07/12 06:00
MHDA- 2017/06/15 06:00
PMCR- 2017/02/01
CRDT- 2016/07/12 06:00
PHST- 2016/07/12 06:00 [pubmed]
PHST- 2017/06/15 06:00 [medline]
PHST- 2016/07/12 06:00 [entrez]
PHST- 2017/02/01 00:00 [pmc-release]
AID - 10.5551/jat.32409 [doi]
PST - ppublish
SO  - J Atheroscler Thromb. 2017 Feb 1;24(2):157-168. doi: 10.5551/jat.32409. Epub 2016 
      Jul 8.